Sanofi Pasteur Inc.

Fernando Noriega

Yves Girerd-Chambaz

Nadia Tornieporth

Betzana Zambrano

Mélanie Saville

Alain Bouckenooghe

Nicholas Jackson

Eric Plennevaux

Mark Boaz

Thomas Papa

Diana Coronel

Tram Anh Wartel

The present invention is directed to a method of booster vaccination and to a vaccine composition for use in such a method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of serotypes 1 to 4 of dengue virus and was dengue na&#xef;ve before said primary vaccination, said composition comprising a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, wherein said booster vaccination results in a 2-fold increase in the neutralizing antibody titre against each of serotypes 1 to 4. The invention is also directed to a method of inducing in a human subject a neutralizing antibody response comprising the administration of a vaccine composition, or to a vaccine composition for use in such a method, said composition comprising a dengue antigen of each of serotypes 1 to 4, or a nucleic acid construct capable of expressing in said subject a dengue antigen of each of serotypes 1 to 4; wherein said composition is administered as a primary vaccination, followed by a booster vaccination, and wherein the human subject is initially dengue na&#xef;ve.

Compositions for booster vaccination against dengue

The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.

Vaccine compositions against dengue virus diseases

The present invention relates to a yellow fever (YF) vaccine for use in a method for inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said yellow fever vaccine to a human subject together with a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4. This invention also pertains to a tetravalent dengue vaccine which comprises a live attenuated dengue virus of each of serotypes 1 to 4 for use in a method of inducing a protective immune response against yellow fever, wherein said method comprises concomitantly administering said tetravalent dengue vaccine to a human subject together with a yellow fever (YF) vaccine.

Concomitant dengue and yellow fever vaccination

Growing community of inventors

Cresco, PA, United States of America

Fernando Noriega